Gallant Pet develops mesenchymal stem cell therapies to treat inflammatory and immune-mediated diseases in pets, targeting the root causes of conditions that lead to pain and limited mobility. Their approach aims to regenerate healthy tissue and improve the quality of life for pets with few existing treatment options.
Funding
$93.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pets suffering from inflammatory and immune-mediated diseases often have limited treatment options, leading to pain, reduced mobility, and a diminished quality of life. Current treatments primarily address symptoms rather than the underlying causes of these conditions.
Solution
Gallant Pet is developing stem cell therapies designed to target the root causes of inflammatory and immune-mediated diseases in pets. Their mesenchymal stem cell (MSC) therapies aim to regenerate healthy tissue, reduce inflammation and scarring, and increase blood supply, thereby restoring pets' bodies through natural biological mechanisms. Gallant's approach offers a potential solution for pets with conditions where existing treatments are inadequate.
Target Audience
The primary target audience includes veterinarians and pet owners seeking advanced treatment options for inflammatory and immune-mediated diseases in pets.
Features
- Mesenchymal stem cell (MSC) therapies targeting the root cause of disease.
- Focus on regeneration of healthy tissue.
- Reduction of inflammation and scarring.
- Increase in blood supply to affected areas.
- Development of off-the-shelf stem cell platform.
- Clinical trials pipeline exploring treatments for a range of diseases.